Onkologie. 2024:18(1):13-17 | DOI: 10.36290/xon.2024.003

Non-surgical treatment of cervical cancer

Igor Sirák1, Denisa Pohanková1, Miroslav Hodek1, Munachiso Ndukwe2, Ivan Práznovec2
1 Klinika onkologie a radioterapie, FN Hradec Králové
2 Porodnická a gynekologická klinika, FN Hradec Králové

Cervical cancer remains a significant social and medical problem in the Czech Republic despite a decrease in incidence and effective prevention measures. Every year, over 700 cases of malignant cervix disease are diagnosed in the country, and about 300 patients die from the disease. However, interdisciplinary cooperation, the expertise of individual healthcare professionals (such as doctors, nurses, medical physicists, and assistants), modern equipment, and the availability of innovative drugs have contributed to an improving prognosis for patients. This review article highlights the current procedures and recommendations for non-surgical treatment of cervical cancer.

Keywords: cervical carcinoma, radiotherapy, brachytherapy, chemotherapy, immunotherapy.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sirák I, Pohanková D, Hodek M, Ndukwe M, Práznovec I. Non-surgical treatment of cervical cancer. Onkologie. 2024;18(1):13-17. doi: 10.36290/xon.2024.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guideline for the management of patients with cervical cancer - update 2023. Int J Gynecol Cancer. 2023;33:649-666. Go to original source... Go to PubMed...
    2. Mileshkin LR, Moore KN, Barnes EH, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomized, phase III trial. Lancet Oncol. 2023;24(5):468-482. Go to original source... Go to PubMed...
    3. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;32:198-202. Go to original source... Go to PubMed...
    4. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 2003;9:425-432. Go to original source... Go to PubMed...
    5. Bonomi P, Blessing JA, DiSaia PJ, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology study. J Clin Oncol. 1985;3:1079-1085. Go to original source... Go to PubMed...
    6. Omura GA, Blessing JA Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifofamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;17:165-171. Go to original source... Go to PubMed...
    7. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:1832-1837. Go to original source... Go to PubMed...
    8. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-3119. Go to original source... Go to PubMed...
    9. Long HJ, 3rd, Bundy BN, Grendys EC, Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633. Go to original source... Go to PubMed...
    10. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009;27:4649-4655. Go to original source... Go to PubMed...
    11. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299-303. Go to original source... Go to PubMed...
    12. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) [abstract]. J Clin Oncol. 2012;30(Suppl 15):Abstract 5006. Go to original source...
    13. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. Go to original source... Go to PubMed...
    14. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent or metastatic cervical cancer. N Engl J Med. 2022 385;20:1856-1864. Go to original source... Go to PubMed...
    15. Oaknin A, Monk BJ, Polastro L, et al. Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis. Ann Oncol. 2022;33:suppl 7:S781. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.